Review
Published on 31 Mar 2014
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
in Pediatric Oncology
Frontiers in Oncology
doi 10.3389/fonc.2014.00063
- 33,597 views
- 117 citations


